Marcie L. Riches
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marcie L. Riches has a total of 290 co-authors. Here are the top co-authors by number of shared publications:
Min Chen
Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin
7 shared publications- Hillard Michael Lazarus
Department of Medicine, Division of Hematology and Oncology, Case Western Reserve University, Cleveland, OH, USA
4 shared publications - Jonathan R. Ptachcinski
Department of Pharmacy University of North Carolina Medical Center Chapel Hill NC USA
4 shared publications Mary Eapen
Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin
4 shared publicationsSiddhartha Ganguly
Division of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, Kansas
4 shared publicationsSteven M. Devine
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be The Match, Minneapolis, Minnesota
4 shared publications
Latest Publications
- 12 August 2025
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 64 (11) , 1621-1637
A Tacrolimus Population Pharmacokinetic Model for Adult Allogeneic Hematopoietic Cell Transplant Recipients Provides Clinical Opportunities for Precision Dosing
Background Tacrolimus is a cornerstone of acute graft-versus-host disease (aGVHD) prophylaxis in allogeneic hematopoietic cell transplant (allo-HCT) recipients. However, a narrow therapeutic index and high interindividual variability in pharmacokinetics (PK) make starting dose selection a major challenge in clinical practice. Methods Data from two PK studies conducted at the University of North Carolina Medical Center (UNCMC) were used to develop an oral tacrolimus population pharmacokinetic (popPK) model specific to adult allo-HCT recipients. Monte Carlo simulations were performed to compare the likelihood of achieving the UNCMC institutional target trough concentration range (ITR) (5–10 ng/mL) on the day of transplant (D0) under the current institutional dosing protocol, dosing recommendations from the Clinical Pharmacogenetics Implementation Consortium (CPIC), and model-derived dosing recommendations. Results In total, 290 allo-HCT recipients contributed a total of 906 PK samples to the final analysis. A two-compartment popPK model adequately described the PK data. Population typical values of apparent clearance (TVCL/F) for 70 kg individuals receiving reduced intensity conditioning were 0.33 L/h/kg for CYP3A5 poor metabolizers (PMs) and 0.70 L/h/kg for intermediate and normal metabolizers (IMs and NMs). The probability of the population-level average D0 trough concentration being within the UNCMC ITR under the current UNCMC weight-based dosing protocol, CPIC-based, and model-derived dosing strategies were estimated to be 37%, 45%, and 76%, respectively. CYP3A5 IMs and NMs were predicted to require a 100% dose increase relative to CYP3A5 PMs. Conclusions We propose a new oral tacrolimus dosing strategy for adult allo-HCT recipients, which suggests the current weight-based dosing paradigm is insufficient. This new strategy includes CYP3A5 metabolizer phenotypes and conditioning regimen intensity, and could increase the percentage of allo-HCT recipients achieving target concentrations on D0. Clinical Trial Registration Number Clinicaltrials.gov NCT04645667
- 12 August 2025
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 64 (11) , 1621-1637
A Tacrolimus Population Pharmacokinetic Model for Adult Allogeneic Hematopoietic Cell Transplant Recipients Provides Clinical Opportunities for Precision Dosing
Background Tacrolimus is a cornerstone of acute graft-versus-host disease (aGVHD) prophylaxis in allogeneic hematopoietic cell transplant (allo-HCT) recipients. However, a narrow therapeutic index and high interindividual variability in pharmacokinetics (PK) make starting dose selection a major challenge in clinical practice. Methods Data from two PK studies conducted at the University of North Carolina Medical Center (UNCMC) were used to develop an oral tacrolimus population pharmacokinetic (popPK) model specific to adult allo-HCT recipients. Monte Carlo simulations were performed to compare the likelihood of achieving the UNCMC institutional target trough concentration range (ITR) (5–10 ng/mL) on the day of transplant (D0) under the current institutional dosing protocol, dosing recommendations from the Clinical Pharmacogenetics Implementation Consortium (CPIC), and model-derived dosing recommendations. Results In total, 290 allo-HCT recipients contributed a total of 906 PK samples to the final analysis. A two-compartment popPK model adequately described the PK data. Population typical values of apparent clearance (TVCL/F) for 70 kg individuals receiving reduced intensity conditioning were 0.33 L/h/kg for CYP3A5 poor metabolizers (PMs) and 0.70 L/h/kg for intermediate and normal metabolizers (IMs and NMs). The probability of the population-level average D0 trough concentration being within the UNCMC ITR under the current UNCMC weight-based dosing protocol, CPIC-based, and model-derived dosing strategies were estimated to be 37%, 45%, and 76%, respectively. CYP3A5 IMs and NMs were predicted to require a 100% dose increase relative to CYP3A5 PMs. Conclusions We propose a new oral tacrolimus dosing strategy for adult allo-HCT recipients, which suggests the current weight-based dosing paradigm is insufficient. This new strategy includes CYP3A5 metabolizer phenotypes and conditioning regimen intensity, and could increase the percentage of allo-HCT recipients achieving target concentrations on D0. Clinical Trial Registration Number Clinicaltrials.gov NCT04645667
- Top Cited PapersOpen Access
- 15 March 2023
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 29 (6) , 346.e1-346.e10
Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
- 15 March 2023
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 29 (6) , 346.e1-346.e10
Top Cited PapersOpen AccessReal-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
- Open Access
- 4 July 2022
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (10) , 696.e1-696.e7
Clinical Characteristics and Outcomes of COVID-19 in Pediatric and Early Adolescent and Young Adult Hematopoietic Stem Cell Transplant Recipients: A Cohort Study
- 4 July 2022
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (10) , 696.e1-696.e7
Open AccessClinical Characteristics and Outcomes of COVID-19 in Pediatric and Early Adolescent and Young Adult Hematopoietic Stem Cell Transplant Recipients: A Cohort Study
- Top Cited PapersOpen Access
- 19 April 2022
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (7) , 409.e1-409.e10
Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes
- 19 April 2022
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (7) , 409.e1-409.e10
Top Cited PapersOpen AccessUpdated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes
- 1 April 2022
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 61 (2) , 103303
Plerixafor strategies for autologous hematopoietic cell transplant mobilization: A comparison of efficacy and cost
- 1 April 2022
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 61 (2) , 103303
Plerixafor strategies for autologous hematopoietic cell transplant mobilization: A comparison of efficacy and cost
- Open Access
- 1 December 2021
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 27 (12) , 1021.e1-1021.e5
Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia
- 1 December 2021
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 27 (12) , 1021.e1-1021.e5
Open AccessSafety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia
- Open Access
- 2 October 2021
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 27 (12) , 993.e1-993.e8
Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy
- 2 October 2021
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 27 (12) , 993.e1-993.e8
Open AccessPlanned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy
- Open Access
- 26 September 2021
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (1) , 48.e1-48.e10
Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome
- 26 September 2021
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (1) , 48.e1-48.e10
Open AccessPost-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome
- Open Access
- 27 August 2021
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 27 (11) , 885-907
Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year
- 27 August 2021
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 27 (11) , 885-907
Open AccessBlood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year
- 26 August 2021
- Published by Wolters Kluwer Health in Current Opinion in Hematology
- Vol. 28 (6) , 389-393
The new world: hematopoietic stem cell transplant during a pandemic
Purpose of review: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) impacted every facet of hematopoietic cell transplantation. This article reviews the adjustments to recipient and donor care that occurred in response to this unprecedented event. Recent findings: Transplant centers modified algorithms, patient flow, education, and how we provided care. Our donor center partners reworked how donors were evaluated and products delivered to the transplant center. Our professional societies provided guidelines for patient and donor care and rapidly modified these based upon the never-ending stream of new data learned about SARS-CoV-2. Our research organizations provided rapid analyses to ensure the care modifications necessitated did not have a profound negative impact on our patients or donors. Summary: The efforts of transplant providers and donor centers worldwide allowed patients to receive the transplant needed with assurances that they were receiving the best care available despite the worldwide challenge.
- 26 August 2021
- Published by Wolters Kluwer Health in Current Opinion in Hematology
- Vol. 28 (6) , 389-393
The new world: hematopoietic stem cell transplant during a pandemic
Purpose of review: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) impacted every facet of hematopoietic cell transplantation. This article reviews the adjustments to recipient and donor care that occurred in response to this unprecedented event. Recent findings: Transplant centers modified algorithms, patient flow, education, and how we provided care. Our donor center partners reworked how donors were evaluated and products delivered to the transplant center. Our professional societies provided guidelines for patient and donor care and rapidly modified these based upon the never-ending stream of new data learned about SARS-CoV-2. Our research organizations provided rapid analyses to ensure the care modifications necessitated did not have a profound negative impact on our patients or donors. Summary: The efforts of transplant providers and donor centers worldwide allowed patients to receive the transplant needed with assurances that they were receiving the best care available despite the worldwide challenge.